AVBP Stock Analysis: ArriVent BioPharma, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 821m USD | 12M Return: 3.8% | US04272N1028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.8M
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ArriVent BioPharma (AVBP) is a clinical-stage biopharmaceutical company developing oncology therapies for cancers with high unmet need. The companys lead candidate, firmonertinib, is an oral tyrosine kinase inhibitor (TKI) being tested in a Phase 3 trial for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, along with Phase 1b studies in other EGFR mutation subsets. TKIs are a well-established class of targeted cancer drugs designed to block enzymes that drive tumor growth.
The pipeline also includes ARR-217, an antibody-drug conjugate (ADC) for gastrointestinal cancers, plus three early-stage solid tumor programs (ARR-002, ARR-421, ARR-173). ADCs are a targeted therapy format that links a monoclonal antibody to a cytotoxic payload to deliver treatment directly to cancer cells. ArriVents broader pipeline is supported by collaborations with several China-based biopharma firms, reflecting the industrys common use of cross-border licensing and co-development deals to access candidates and geographic markets.
As a clinical-stage company, ArriVent has no approved products or product revenue, and its value is tied to clinical trial outcomes, regulatory milestones, and the success of its development partnerships. The company was incorporated in 2021, is headquartered in Newtown Square, Pennsylvania, and completed its NASDAQ IPO in January 2024.
- Firmonertinib Phase 3 exon 20 NSCLC data readout approaches
- FDA approval pathway and BLA submission timeline drive valuation
- Cash burn rate and runway constrain clinical-stage operations
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.37 > 0.02 and ΔFCF/TA 9.51 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 > 3% & CFO -147.9m > Net Income -163.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.6m) vs 12m ago 36.00% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.93 (Total Current Assets 394.2m - Total Current Liabilities 27.8m) / Total Assets 394.7m |
| B: -1.26 (Retained Earnings -497.9m / Total Assets 394.7m) |
| C: -0.53 (EBIT TTM -175.9m / Avg Total Assets 332.1m) |
| D: 13.16 (Book Value of Equity 366.8m / Total Liabilities 27.9m) |
| Altman-Z'' = 12.23 = AAA |
As of October 23, 2026, the stock is trading at USD 19.20 with a total of 843,677 shares traded. Over the past week, the price has changed by +14.35%, over one month by -36.68%, over three months by -36.93% and over the past year by +3.84%.
Current recommended Stop Loss: 17.00 (which is 11.5% or 1.2 ATR below the current price).
ArriVent BioPharma, Common has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy AVBP.
- StrongBuy: 11
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.6 | 12.3% |
P/B = 4.0646
Revenue TTM = 0.0 USD
EBIT TTM = -175.9m USD
EBITDA TTM = -175.9m USD
Long Term Debt = 33.0k USD (estimated: total debt 351k - short term 318k)
Short Term Debt = 318k USD (from shortTermDebt, last quarter)
Debt = 351k USD (from shortLongTermDebtTotal, last quarter) (leases 351k already included)
Net Debt = -372.8m USD (calculated: Debt 351k - CCE 373.1m)
Enterprise Value = 448.7m USD (821.5m + Debt 351k - CCE 373.1m)
Interest Coverage Ratio = unknown (Ebit TTM -175.9m / Interest Expense TTM 0.0)
EV/FCF = -3.03x (Enterprise Value 448.7m / FCF TTM -147.9m)
FCF Yield = -32.97% (FCF TTM -147.9m / Enterprise Value 448.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.14 (Enterprise Value 448.7m / Total Assets 394.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 351k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -139.0m (EBIT -175.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.16 (Total Current Assets 394.2m / Total Current Liabilities 27.8m)
Debt / Equity = 0.00 (Debt 351k / totalStockholderEquity, last quarter 366.8m)
Debt / EBITDA = 2.12 (negative EBITDA) (Net Debt -372.8m / EBITDA -175.9m)
Debt / FCF = 2.52 (negative FCF - burning cash) (Net Debt -372.8m / FCF TTM -147.9m)
Total Stockholder Equity = 325.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.30% (Net Income -163.7m / Total Assets 394.7m)
RoE = -50.26% (Net Income TTM -163.7m / Total Stockholder Equity 325.8m)
RoCE = -54.00% (EBIT -175.9m / Capital Employed (Equity 325.8m + L.T.Debt 33.0k))
RoIC = -37.85% (negative operating profit) (NOPAT -139.0m / Invested Capital 367.2m)
WACC = 7.83% (E(821.5m)/V(821.8m) * Re(7.83%) + D(351k)/V(821.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.96 | Cagr: 16.91%
[DCF] Fair Price = unknown (Cash Flow -147.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.15 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.08 | Chg30d=-0.34% | Revisions=+17% | Analysts=10
EPS current Year (2026-12-31): EPS=-4.22 | Chg30d=+2.76% | Revisions=+50% | GrowthEPS=+2.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.86 | Chg30d=-1.43% | Revisions=-30% | GrowthEPS=+8.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +6% (up=7, down=6)